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Members of the Myocyte Enhancer Factor 2 (MEF2) family of transcription factors play key roles in the development and differentiation
of numerous cell types during mammalian development, including the vascular endothelium. Mef2c is expressed very early in the
development of the endothelium, and genetic studies in mice have demonstrated that mef2c is required for vascular development. However,
the transcriptional pathways involving MEF2C during endothelial cell development have not been defined. As a first step towards identifying
the transcriptional factors upstream of MEF2C in the vascular endothelium, we screened for transcriptional enhancers from the mouse mef2c
gene that regulate vascular expression in vivo. In this study, we identified a transcriptional enhancer from the mouse mef2c gene sufficient to
direct expression to the vascular endothelium in transgenic embryos. This enhancer is active in endothelial cells within the developing
vascular system from very early stages in vasculogenesis, and the enhancer remains robustly active in the vascular endothelium during
embryogenesis and in adulthood. This mef2c endothelial cell enhancer contains four perfect consensus Ets transcription factor binding sites
that are efficiently bound by Ets-1 protein in vitro and are required for enhancer function in transgenic embryos. Thus, these studies identify
mef2c as a direct transcriptional target of Ets factors via an evolutionarily conserved transcriptional enhancer and establish a direct link
between these two early regulators of vascular gene expression during endothelial cell development in vivo.
D 2004 Elsevier Inc. All rights reserved.
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The development of the embryonic vasculature occurs in
two stages known as vasculogenesis and angiogenesis.
Vasculogenesis occurs primarily in two places and results in
the de novo formation of blood vessels from specified
mesodermal progenitor cells. In the yolk sac, extraem-
bryonic cells, called hemangioblasts, aggregate to form
blood islands (Flamme et al., 1997; Oettgen, 2001; Risau0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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then differentiate into an outer layer of endothelial cells and
an inner group of blood cells. The endothelial cells that
originate in the blood islands form a primitive vascular
plexus. Similarly, in the embryo, angioblasts in the lateral
mesoderm differentiate into endothelial cells and initially
form the dorsal aortae and other vessels (Flamme et al.,
1997; Oettgen, 2001; Risau and Flamme, 1995). The
primitive vasculature is remodeled during angiogenesis into
a more complex vascular network through sprouting and
intussusception (growth within itself) to create new vessels
of varying sizes (Burri and Djonov, 2002; Flamme et al.,
1997; Patan, 2004). During angiogenesis, mesenchymal
cells that surround vessels differentiate into smooth muscle
cells and pericytes, which are added to the vessels and275 (2004) 424–434
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are surrounded by smooth muscle cells and smaller vessels
are surrounded by pericytes (Parmacek, 2001).
While much has been learned in recent years regarding
the molecular control of vascular development, many
important questions remain to be addressed, particularly
with regard to the transcriptional networks controlling
vasculogenesis and angiogenesis. One group of transcription
factors that plays a clear role in early endothelial cell
specification and differentiation is the Ets family of winged
helix proteins (Lelievre et al., 2001; Sato, 2001). Members
of this family are defined by the presence of a conserved
DNA binding domain, which folds into a winged helix–
turn–helix motif and binds to the consensus core DNA
sequence GGAW with variable flanking sequences (Lelievre
et al., 2001; Nye et al., 1992; Sharrocks et al., 1997). Of the
nearly 30 mammalian family members so far identified, at
least five, Ets-1, Erg, Fli-1, TEL, and NERF-2, are
expressed in the vasculature during embryonic development
and each has been shown to play an important role in
endothelial-restricted gene expression (Lelievre et al., 2001;
Maroulakou and Bowe, 2000; Sato, 2001).
Ets factors are among the earliest transcriptional regu-
lators of vascular development through their activation of
multiple early endothelial genes. For example, ETS binding
sites have been identified, and shown to be required, within
the enhancers of several critical genes involved in vascular
development, including Flt-1 and Flk-1 and the angiopoie-
tin receptor genes Tie and Tie-2 (Dube et al., 1999; Iljin et
al., 1999; Kappel et al., 2000; Wakiya et al., 1996). The
observation that early markers of endothelial cell develop-
ment are direct downstream targets of Ets proteins strongly
suggests a role for Ets proteins in vasculogenesis and in
endothelial cell specification. The key role of Ets proteins in
endothelial cell development makes it critical to define more
fully the transcription factors that are downstream of Ets in
the pathways controlling vasculogenesis and angiogenesis.
The Myocyte Enhancer Factor 2 (MEF2) family of
transcription factors plays an important role in transcrip-
tional activation during vascular development. There are
four mef2 genes in vertebrates, mef2a-d, and a single mef2
gene in Drosophila (Black and Olson, 1998). MEF2 factors
are members of the MADS box superfamily of transcription
factors and are distinguished from other MADS box
proteins by the presence of the highly conserved MEF2
domain adjacent to the MADS box (Black and Olson,
1998). All four vertebrate mef2 genes are expressed in the
vasculature (Edmondson et al., 1994; Firulli et al., 1996; Lin
et al., 1998; Subramanian and Nadal-Ginard, 1996). In
particular, mef2a and mef2c are expressed in the early
embryonic vasculature (Dodou et al., 2004; Edmondson et
al., 1994; Lin et al., 1998; Subramanian and Nadal-Ginard,
1996), and both genes appear to play crucial roles in
vascular gene expression. Mutations in the human mef2a
gene have been observed in patients with inherited coronary
artery disease (Wang et al., 2003), and targeted inactivationof the mef2c gene in mice resulted in profound cardiac and
vascular defects and embryonic lethality at 9.5 dpc (Bi et al.,
1999; Lin et al., 1997, 1998). In mef2c knockout mice,
endothelial cells were initially present but failed to organize
correctly, suggesting an endothelial cell differentiation
defect or a defect in angiogenesis. However, despite the
early expression of mef2c in endothelial cells and the
requirement for MEF2C in vascular development, nothing
has been elucidated regarding its transcriptional regulation
in endothelial cells. Thus, it has not been clear how MEF2C
fits into the transcriptional pathways controlling vascular
development and endothelial cell differentiation.
Here, we describe the identification of an intronic
enhancer from the murine mef2c gene that is sufficient to
direct expression to the vascular endothelium in transgenic
embryos. This enhancer is active in endothelial cells within
the developing vascular system from the earliest stages of
vasculogenesis in the yolk sac and embryo, and the
enhancer remains robustly active throughout embryonic
development. This mef2c vascular endothelial enhancer
contains four perfect consensus Ets transcription factor
binding sites that are efficiently bound by Ets-1 protein in
vitro and are required for enhancer function in transgenic
embryos. Thus, these studies identify mef2c as a direct
transcriptional target of Ets factors and establish a direct link
between these two early regulators of vascular gene
expression during endothelial cell development in vivo.Materials and methods
Cloning and mutagenesis
A 4655-bp fragment of the mouse mef2c gene, called F7,
was generated by PCR and cloned as an XmaI fragment into
the XmaI site of the transgenic reporter plasmid HSP68-lacZ
(Kothary et al., 1989) to generate plasmid mef2c-F7-lacZ.
F7-2 was generated by NsiI digestion and cloning into the
PstI site of HSP68-lacZ. F7-3 was generated by cleavage
with BclI–BamHI, followed by cloning into the BamHI site
of pBluescript SKII+ and subsequent subcloning as a XhoI–
XmaI fragment into the corresponding sites in HSP68-lacZ.
F7-4 was generated by excising the 441-bp sequence between
the BclI and BamHI sites in F7 and subsequent religation of
the compatible cohesive ends. Mutations were introduced
into plasmidmef2c-F7-2-lacZ for analysis in transgenic mice.
The following mutant sequences were created in the context
of fragment F7-2: mETS-A, 5V-gctcagagaagcttgtggagagtt-3V;
mETS-B, 5V-gtttagggtaccaagcacctttac-3V; mETS-C, 5V-gctga-
catcatatgctagcctggc-3V; mETS-D [F7-2(mutD)], 5V-
gtgtgcgtgtcagctgccattctg-3V. To create F7-2(mutABCD), and
F7-2(mutAD), the indicated mutations were introduced
sequentially. The entire sequence of each mutant fragment
was confirmed by sequencing on both strands. The GenBank
accession number for the sequence of the 4655-bp mef2c F7
endothelial cell enhancer is AY613436.
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Transgenic reporter fragments were digested away from
the plasmid backbone with XhoI–NotI, gel purified, and
suspended in 5 mM Tris–HCl, 0.2 mM EDTA, pH 7.4, at a
concentration of 2 Ag/ml for pronuclear injection as
described previously (Hogan et al., 1994). Injected embryos
were implanted into pseudopregnant CD-1 females, and
embryos were collected at indicated times for F0 analysis or
were allowed to develop to adulthood for establishment of
transgenic lines. Small amounts of yolk sac were left on
embryos obtained in transient transgenic analyses for X-gal
staining, but the majority of the yolk sac was removed for
DNA extraction for use in genotyping. DNA was extracted
from the yolk sac of embryos or from tail biopsies from
mice by digestion in tail lysis buffer (100 mM NaCl, 25 mM
EDTA, 1% sodium dodecyl sulfate, 10 mM Tris–Cl, 200 Ag/
ml of proteinase K, pH 8.0) at 568C overnight. Digested
samples were extracted once with phenol–chloroform and
ethanol precipitated. DNA preparations were digested with
SacI and analyzed by Southern blotting using a radiolabeled
lacZ probe. All experiments using animals complied with
federal and institutional guidelines and were reviewed and
approved by the UCSF Institutional Animal Care and Use
Committee.
X-gal staining and immunohistochemistry
h-galactosidase expression in lacZ transgenic embryos or
tissues was detected by X-gal staining of embryos or by
antibody staining of sectioned tissue. X-gal staining of
embryos was performed as described previously (Dodou et
al., 2003). Transverse sections from X-gal-stained embryos
and tissues were prepared as described previously (Ander-
son et al., 2004). Sections were counterstained with Neutral
Fast Red to visualize embryonic structures. For immuno-
histochemical detection of h-galactosidase, smooth muscle
a-actin, and PECAM-1 (CD31), lacZ transgenic embryos
were collected at the indicated times and fixed overnight in
4% paraformaldehyde in PBS. PECAM-1 antibody staining
of whole mount embryos was adapted from a previously
described procedure (Schlaeger et al., 1995) using the
Vector SG substrate kit (Vector, SK-4700) for the perox-
idase reaction. Embryos were then fixed overnight, embed-
ded in paraffin, and sectioned as described (Anderson et al.,
2004). Sections were analyzed for transgene expression by
immunohistochemistry using rabbit anti-h-galactosidase
(ICN) as primary antibody diluted 1 in 300 in 3% normal
goat serum. Primary antibody binding was detected using
Oregon Green-conjugated goat anti-rabbit secondary anti-
body diluted 1 in 300 in 3% normal goat serum. For
detection of smooth muscle a-actin and h-galactosidase
expression, lacZ transgenic embryos were fixed, embedded,
and sectioned as described above. The primary antibodies
were added to sections simultaneously. Anti-h-galactosidase
and the goat anti-rabbit antibodies were used as describedabove. Anti-smooth muscle a-actin (Sigma, clone 1A4) was
diluted 1 in 50 in 3% normal goat serum, and the secondary
antibody was tetramethyl rhodamine isocyanate (TRITC)-
conjugated anti-mouse (Sigma) diluted 1 in 300 in 3%
normal goat serum.
Electrophoretic mobility shift assay (EMSA)
DNA binding reactions were performed as described
previously (Dodou et al., 2003). Briefly, double stranded
oligonucleotides were labeled with 32P-dCTP, using Klenow
to fill in overhanging 5V ends, and purified on a non-
denaturing polyacrylamide-TBE gel. Binding reactions were
pre-incubated at room temperature in 1 binding buffer (40
mM KCl, 15 mM HEPES pH 7.9, 1 mM EDTA, 0.5 mM
DTT, 5% glycerol) containing recombinant truncated Ets-1
protein, 1 Ag of poly dI-dC, and competitor DNA (50-fold
excess where indicated) for 10 min before probe addition.
Reactions were incubated an additional 20 min at room
temperature after probe addition and electrophoresed on a
10% nondenaturing polyacrylamide gel. The truncated
version of murine Ets-1 was generated from plasmid
pCITE-Ets-1(tr) using the TNT Quick Coupled Transcrip-
tion/Translation System as described in the manufacturer’s
directions (Promega). pCITE-Ets-1(tr) was created by
cloning the cDNA region encoding amino acids 336–441
and the stop codon from the Ets-1 protein into the
translational enhancement vector pCITE-2A (Novagen).
This region of Ets-1 encodes the 85 amino acid ETS
domain but not an auto-inhibitory domain, and this region
has been shown to efficiently bind to bona fide ETS sites
(Nye et al., 1992). The stromelysin ETS-1 control Ets-1
binding site and mutant oligonucleotides for that binding
site were adapted from previously described sequences
(Wasylyk et al., 1991) and the sense strand sequences were
as follows: St, 5V-gtcgagcaggaagcatttcctggtcga-3V; mSt, 5V-
gtcgagcaacaagcatttgttggtcga-3V. The sense strand sequences
of the mef2c F7 oligonucleotides used for EMSA were:
ETS-A, 5V-gctcagagaaggaagtggagagtt-3V; mutETS-A, 5V-gctca-
gagaagcttgtggagagtt-3V; ETS-B, 5V-gtttagggaaggaagcacctttac-
3V; mutETS-B, 5V-gtttagggtaccaagcacctttac-3V; ETS-C, 5V-
gctgacatcatatccttccctggc-3V; mutETS-C, 5V-gctgacatcatatgc-
tagcctggc-3V; ETS-D, 5V-gtgtgcgtgtttcctgccattctg-3V; mutETS-
D, 5V-gtgtgcgtgtcagctgccattctg-3V.Results
Identification of an endothelial cell-specific enhancer from
mef2c
The mef2c gene is expressed in multiple distinct cell
types during mammalian development, including skeletal,
cardiac, and smooth muscles, neural crest and the vascular
endothelium (Dodou et al., 2004; Edmondson et al., 1994;
Lin et al., 1998). While mef2c expression is broad, it is not
Fig. 1. Schematic diagram of the mef2c locus and endothelial cell-specific
mef2c enhancer transgene. The top line represents a 120 kb region from the
5Vend of the mouse mef2c locus, including the first 6 exons (black vertical
lines), which are numbered. MADS (exon 5) refers to the first coding exon
of mef2c. This exon encodes amino acids 1–17 of the highly conserved
MADS domain. MEF2 (exon 6) refers to the second coding exon of mef2c.
This exon encodes the remainder of the MADS domain and the adjacent
MEF2 domain (amino acids 18–86). The red box represents the F7
fragment of mef2c. F7 encompasses the endothelial cell-specific enhancer
described in the present study. The lower line depicts transgene construct,
mef2c-F7-lacZ, which contains the 4655 bp F7 fragment, including
untranslated exon 4, subcloned into the transgenic reporter plasmid
HSP68-lacZ. Yellow box, HSP68 promoter; Blue box, lacZ reporter gene;
Purple box, SV40 splice and polyadenylation (polyA) sequence.
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enhancers from the mouse mef2c gene that are sufficient
to direct expression exclusively to skeletal muscle (Dodou
et al., 2003; Wang et al., 2001) and to the anterior regions of
the secondary heart field (Dodou et al., 2004) in transgenic
mice. Thus, evidence to date supports a model for mef2c
regulation based on multiple, separate transcriptionalFig. 2. The mef2c-F7-lacZ transgene is expressed in the vasculature throughout em
or tissues are shown. Transgenic embryos collected and stained inside of the yolk
extraembryonic expression of the transgene. X-gal staining was detected first in the
vascular plexus (VP) by 7.75 dpc. Strong expression of lacZ was observed within
was clearly detected in the dorsal aortae (DA), the endocardium, and the developi
persisted in extraembryonic tissue, with intense X-gal staining seen in the vascular
was detected in all blood vessels of the developing embryo (panel E), and throu
throughout embryonic development, with X-gal staining at 11.0 dpc (panel G) an
Expression of the mef2c-F7-lacZ transgene was also detected in the vasculature in
and from an adult mouse (panel J) is shown as an example from each stage. Dorsal
(D–J). AL, allantois; EC, ectoplacental cone; ST, stomach; V, vasculature. Arrowenhancers that each control expression in a defined lineage.
We have recently identified a 120 kb region from the mouse
mef2c gene that is sufficient to direct the complete pattern of
endogenous mef2c expression, including in all three muscle
lineages, neural crest, and vascular endothelium (Dodou
et al., 2004). As a first step to identify discrete enhancer
elements within the mouse mef2c locus, we compared the
sequence of the mouse and human mef2c genes in the 120
kb sufficiency region (Fig. 1) using VISTA and BLAST
analyses (Altschul et al., 1990; Mayor et al., 2000). These
analyses identified 11 regions of significant homology,
which were analyzed for enhancer function by cloning each
into the transgenic reporter plasmid HSP68-lacZ (Kothary
et al., 1989) and testing for activity in transgenic embryos.
One of these regions, termed F7, was located from 4803 to
140 bp upstream of the translational initiation site in mef2c
(Fig. 1). This highly conserved region encompassed the
fourth noncoding exon and was immediately upstream of
the first coding exon (Exon 5), which encodes the highly
conserved MADS domain (Fig. 1).
The F7 fragment of mef2c was sufficient to direct
expression to the vascular endothelium throughout develop-
ment and in adults in transgenic mice (Fig. 2). Faint
expression in isolated cells within blood islands in the yolk
sac was first apparent at 7.5 dpc (Fig. 2A) but became much
more robust in the yolk sac and dorsal aortae within the
embryo by 7.75 dpc (Fig. 2B). By 8.0 dpc, expression wasbryonic development and in the adult. Representative X-gal-stained embryos
sac (YS) at 7.5 dpc (panel A) and 7.75 dpc (panel B) demonstrate the early
blood islands (BL) at 7.5 dpc and then at greater intensity in the developing
the developing intraembryonic vasculature by 8.0 dpc when X-gal staining
ng blood vessels of the neural plexus (NP) (panel C). Transgene expression
plexus of the yolk sac at 8.5 dpc (panel D). By 9.5 dpc transgene expression
ghout the yolk sac vasculature (panel F). Transgene expression continued
d 13.5 dpc (panel H) detected in all blood vessels and in the endocardium.
the fetus and adult. A stomach dissected from a 16.5-dpc embryo (panel I)
view (A, B); parafrontal view from the right (C); lateral view from the right
heads mark the endocardium.
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plexus (Fig. 2C). Expression directed by the mef2c F7
enhancer to the yolk sac was obvious in the primitive
vascular plexus stage at 8.5 dpc (Fig. 2D) and in the more
organized tree-like structure of the yolk sac at 9.5 dpc (Fig.
2F). Transgene expression in the embryo at 9.5 dpc was
robust and was present throughout the vascular endothe-
lium, including large vessels, capillaries, and the endocar-
dium (Fig. 2E). This pattern of expression, which marked
the entire vascular endothelium, persisted throughout the
remainder of embryonic development (Figs. 2G and H).
Transgene expression was also detected in the vasculature at
16.5 dpc, including the stomach vasculature (Fig. 2I) and in
the vasculature in all other tissues (data not shown). LacZ
expression was also present throughout the adult vascular
system (Fig. 2J), but expression often appeared patchy,
suggesting that the enhancer was active only in a subset of
endothelial cells or that it was activated transiently in the
adult vascular endothelium such that at any given time not
all cells appeared lacZ-positive.
To define further the expression of lacZ directed by the
mef2c F7 enhancer, we examined transverse sections cut
from X-gal-stained transgenic embryos. Consistent with the
expression pattern observed in whole mount stained
embryos, h-galactosidase activity was apparent in theFig. 3. The mef2c F7 enhancer directs endothelial expression. Representa-
tive transverse sections of lacZ transgenic embryos are shown at 8.5 dpc
(A), 9.5 dpc (B, C), 11.5 dpc (D–L), 13.5 dpc (M, N), and 16.5 dpc (O).
h-galactosidase activity was detected by staining with X-gal before
sectioning (A–F, M–O), or by immunohistochemistry using an anti-h-
galactosidase polyclonal antibody (H, K). At 8.5 and 9.5 dpc, X-gal
staining was clearly detectable in the cardinal veins, dorsal aortae and
endocardium (A, B). By 9.5 dpc, transgene expression was also detected in
the microvasculature of the neural plexus (B) and staining appears restricted
to the endothelial cells of the vasculature (C). X-gal staining could also be
observed in a limited number of circulating blood cells, which likely
reflected the common origins of endothelial cells and some blood cells (C,
F). At 11.5 dpc, lacZ expression directed by the mef2c endothelial cell
enhancer was present throughout the vasculature, with X-gal staining seen
in the endothelium of major vessels, including the cardinal vein and
branchial arch arteries (D); in the microvasculature of the neural plexus (E);
and in the endocardium (F). The expression of h-galactosidase in blood
vessels was compared to the expression of the endothelial cell marker
PECAM and the expression of smooth muscle a-actin (SMaA) (G–L).
PECAM staining (blue/gray) (G) and h-galactosidase (green) (H) were
detected in the same cells on the same section in the merged image (I).
SMaA (red) (J) and h-galactosidase (green) (K) were not detected in the
same cells in the merged image (L). h-galactosidase expression was always
inside of the SMaA expression, indicating that the mef2c-F7-lacZ
transgene is not expressed in smooth muscle cells and is specific to
endothelial cells. The mef2c-F7-lacZ transgene continued to direct
endothelial-specific expression at later stages of development in the
microvasculature at 13.5 dpc (M) and in major vessels at 13.5 dpc (N)
and 16.5 dpc (O). Expression was not observed in smooth muscle cells at
any stage examined. BAA, branchial arch arteries; CV, cardinal vein; DA,
dorsal aorta; EC, endothelial cells; Ht, heart; NP, neural plexus; NT, neural
tube; Lu, lumen; MV, microvasculature; Myo, myocardium; SMC, smooth
muscle cells. Arrowheads mark the endocardium. In all panels, dorsal is at
the top. Scale bar is equal to 100 Am except in panels C, F, N, and O, where
the scale bar is equal to 50 Am.endothelial cells of arteries and veins and endocardium at
8.5 dpc (Fig. 3A). The same pattern of h-galactosidase
expression continued at 9.5 and 11.5 dpc, where all
endothelial cells in the embryo and yolk sac were positively
stained with X-gal (Figs. 3B–F). Examination of X-gal
staining of vessels at higher magnification indicated that the
cells immediately adjacent to the vessel lumen were positive
for h-galactosidase, whereas other cells surrounding vessels
were negative for transgene expression, indicating expres-
sion in endothelial cells (Figs. 3C, E, and F).
To test directly whether the expression of the transgene
was restricted to endothelial cells, we compared the
expression of h-galactosidase to the expression of the
endothelial cell-specific marker PECAM on transverse
sections by immunohistochemistry using antibodies directed
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h-galactosidase (Fig. 3H) were both restricted to cells
immediately adjacent to the vessel lumen and the expression
of the two markers overlapped in every embryonic section
examined (Fig. 3I). Because mef2 genes are also expressed
in smooth muscle cells, we wanted to determine if the mef2c
F7 enhancer directed any expression to the smooth muscle
component of the vasculature. Smooth muscle a-actin
expression was easily detectable around arteries at 11.5
dpc (Fig. 3J) but expression did not overlap with the
expression of h-galactosidase directed by the mef2c F7
enhancer (Fig. 3L). Indeed, expression of h-galactosidase
was always immediately adjacent to the vessel lumen in the
endothelial cell compartment of the vessel wall (Fig. 3K),
while expression of smooth muscle a-actin was outside of
the h-galactosidase expressing cells (Fig. 3L). Strong
expression of h-galactosidase in endothelial cells continued
throughout embryonic and fetal development. Expression
directed by the mef2c F7 enhancer was evident in the
endothelial cells of the microvasculature (Fig. 3M) and of
larger vessels at 13.5 dpc (Fig. 3N) and 16.5 dpc (Fig. 3O).
No expression was ever observed in smooth muscle cells at
any stage examined. Interestingly, we also observed
expression in a limited number of circulating blood cells
(Figs. 3C and F), which is consistent with activation of the
enhancer in circulating hemangioblast progenitors of endo-
thelial cells (Choi et al., 1998). Expression in putative
hemangioblast progenitor cells has also been observed for
other endothelial-specific transgenes, including expressionFig. 4. Deletional analysis of the mef2c-F7 fragment identifies a highly conserv
enhancer function in vivo. (A) Schematic diagram of the deletion constructs of the
at the top. Red boxes represent three regions of high sequence homology between
black box represents mef2c untranslated exon 4. The nucleotide positions of each
expression directed by each constructed is summarized by a plus (endothelial expr
line representing each construct. The column on the far right indicates the numbe
vascular endothelium as a fraction of the total number of transgene-positive F0 em
of the deletion constructs depicted in panel Awere collected at 9.5 dpc and X-gal st
and F7-3 also directed strong expression throughout the vascular endothelium
surrounding the highly conserved CR1. Deletion of CR1 (D1049–1489) from F
Arrowheads mark the endocardium.directed by the Tie-2 promoter (Kisanuki et al., 2001).
Taken together, these observations demonstrate the early
activation of this mef2c enhancer in differentiated endothe-
lial cells and their progenitors.
A minimal fragment of the mef2c endothelial enhancer is
required and sufficient for function in vivo
As a first step towards identifying the critical tran-
scription factor binding sites controlling mef2c expression in
the vascular endothelium, we wanted to define a minimal
region of the enhancer that was sufficient for transgene
expression in vivo. Comparison of the mouse and chicken
mef2c genes revealed three small regions of high con-
servation within the mef2c F7 vascular endothelial enhancer,
denoted CR1, CR2, and CR3 (Fig. 4A). We reasoned that
one or more of these conserved regions was likely to be
crucial for enhancer function in vivo so we performed a
deletional analysis to determine which of these regions of
conservation might be important for transgene expression
(Fig. 4).
The F7 construct, described in detail in Figs. 2 and 3,
directed strong, endothelial cell-specific expression in 3 of
3 transgenic lines examined (Fig. 4B). Deletion from the 3V
end of F7 to create a 2346-bp fragment, F7-2, extending
from nucleotides 15 to 2360, resulted in a construct that
was also sufficient for robust, endothelial-specific expres-
sion in transgenic embryos (Fig. 4C). F7-2 contains
approximately half of the original F7 fragment from mef2c,ed 441 bp element that is necessary and sufficient for endothelial-specific
mef2c endothelial cell enhancer. The genomic organization of F7 is depicted
the mouse and chicken mef2c genes, denoted as CR1, CR2, and CR3. The
deletion construct, relative to F7, are denoted on the left, and endothelial
ession) or a minus (no detectable endothelial expression) to the right of the
r of independent transgenic lines or F0 embryos that expressed lacZ in the
bryos or lines examined. (B–E) Representative transgenic embryos for each
ained. F7 directed strong endothelial-specific expression (B). Likewise, F7-2
, including the endocardium (C, D). F7-3 encompasses only the region
7-2 to generate fragment F7-4 completely ablated transgene activity (E).
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conservation (Fig. 4A). This suggested that the CR1 region
might represent a crucial element for directing endothelial
cell-specific expression in transgenic embryos. To test
whether CR1 was sufficient to direct lacZ expression in
vivo, we generated construct F7-3, which contains only
441 nucleotides and extends from nucleotides 1049 to 1489
within the F7 sequence. This region extends just beyond
the highly conserved CR1 in both the 5V and 3Vdirections
(Fig. 4A). F7-3 was sufficient to direct robust expression of
lacZ in five out of six transgenic lines, and expression was
restricted to endothelial cells (Fig. 4D). Because the CR1
was sufficient for expression in vivo, we also tested
whether it was required for enhancer function by creating
construct F7-4, which removes nucleotides 1049–1489
within the context of F7-2 (Fig. 4A). Deletion of this
region of the mef2c F7 enhancer completely ablated
enhancer function in transgenic embryos in all lines
examined (Fig. 4E). These results demonstrate that a small
441-bp region of the mef2c endothelial cell-specific
enhancer encompassing CR1 is necessary and sufficient
for enhancer function in vivo.
The mef2c endothelial enhancer is dependent on Ets
transcription factor binding sites for function in vivo
To help identify specific transcription factor binding sites
within the required and sufficient region of the mef2c F7
endothelial cell-specific enhancer, we analyzed the CR1
element for candidate transcription factor binding sites by
multiple species sequence comparison (Fig. 5). ClustalW
analysis (Thompson et al., 1994) comparing the conserved
region of the enhancer from mouse, human, opossum, and
chicken identified four perfectly conserved candidate bind-
ing sites for Ets transcription factors (Fig. 5). Because
several Ets transcription factors, including Ets-1, have been
shown to play key early roles in vascular endothelial
development, the putative ETS elements in the mef2cFig. 5. The mef2c endothelial cell-specific enhancer contains four perfectly conserv
of the conserved enhancer region from mouse, human, opossum, and chicken iden
factors (red boxes), denoted as ETS-A, -B, -C and -D in a 5Vto 3Vdirection. Aster
species.enhancer represented excellent candidate sites for a potential
role in the regulation of the enhancer.
As a first step to determine whether the candidate ETS
sites in the mef2c endothelial enhancer might represent
bona fide binding sites, we tested each of the four
candidate elements for the ability to compete for Ets-1
binding to the canonical ETS-1 element from the
stromelysin gene (Wasylyk et al., 1991). Ets-1 bound
efficiently to the stromelysin ETS-1 element (Fig. 6A, lane
2) and binding was efficiently competed by a 50-fold
excess of unlabeled stromelysin ETS site probe (Fig. 6A,
lane 3) but not by a mutant version of that probe (Fig. 6A,
lane 4). Each of the ETS sites from the mef2c F7 enhancer
was able to compete for Ets-1 binding to the stromelysin
ETS-1 site, and the competition by the mef2c ETS-D site
for the stromelysin ETS-1 element was as robust as the
competition by the stromelysin ETS-1 site itself (Fig. 6A,
compare lanes 3 and 11). The mef2c ETS-A site also
efficiently competed for Ets-1 binding to the canonical site
(Fig. 6A, lane 5), but not as well as the stromelysin ETS-1
site itself or the mef2c ETS-D site. The mef2c ETS-B and
ETS-C sites also competed for binding (Fig. 6A, lanes 7
and 9) but the competition was weaker than the competi-
tion exhibited by the ETS-A and ETS-D sites. Mutant
versions of each of the four ETS sites from the mef2c F7
enhancer displayed no detectable competition for Ets-1
binding to the canonical site even at 50-fold excess (Fig.
6A, lanes 6, 8, 10, and 12).
Because the mef2c ETS-A and ETS-D sites showed the
most robust competition for Ets-1 binding to the stromelysin
ETS-1 site in Fig. 6A, we examined the ability of Ets-1
protein to bind directly to those two candidate sites (Fig.
6B). Recombinant Ets-1 bound strongly to both the ETS-A
(Fig. 6B, lane 2) and ETS-D (Fig. 6B, lane 8) sites in the
mef2c F7 endothelial enhancer. Binding to the ETS-A site
was efficiently competed by an excess of unlabeled ETS-A
site or by the bona fide ETS-1 site from the stromelysin
gene (Fig. 6B, lanes 3 and 5), but not by mutant versions ofed, candidate ETS binding sites. ClustalW analysis comparing the sequence
tified four perfectly conserved candidate binding sites for Ets transcription
isks denote nucleotides that have been perfectly conserved among all four
Fig. 6. The mef2c endothelial cell enhancer contains multiple high affinity ETS binding sites. (A) Recombinant Ets-1 protein was transcribed and translated in
vitro and used in EMSA with a radiolabeled double-stranded oligonucleotides representing the stromelysin ETS-1 site (lanes 2–12). Lane 1 contains
reticulocyte lysate without recombinant Ets-1 protein (represented by a minus sign). Ets-1 efficiently bound to the stromelysin ETS-1 site (lane 2) and this
binding was efficiently competed by an excess unlabeled wild-type stromelysin ETS-1 site (St) (lane 3) but not by an excess of a mutant form of that site (mSt)
(lane 4). The mef2c ETS-A (lane 5), ETS-B (lane 7), and ETS-C (lane 9) sites also competed for binding of Ets-1 to the stromelysin ETS-1 site, but less
efficiently than the canonical St site (lane 3). Mutant versions of ETS-A, -B, and -C failed to compete for binding to the stromelysin ETS-1 probe even when
present at 50-fold excess (lanes 6, 8, and 10). The mef2c ETS-D element competed for binding of Ets-1 to the stromelysin ETS-1 probe (lane 11) as efficiently
as the canonical St site (lane 3) while a mutant version of the ETS-D site failed to compete for binding when present in 50-fold excess (lane 12). (B)
Recombinant Ets-1 protein was transcribed and translated in vitro and used in EMSAwith radiolabeled double-stranded oligonucleotide probes encompassing
the mef2c ETS-A site (lanes 1–6) and the mef2c ETS-D site (lanes 7–12). Lanes 1 and 7 contain reticulocyte lysate without recombinant Ets-1 protein
(represented by a minus sign). Ets-1 protein bound efficiently to the ETS-A probe (lane 2) and this binding was specific since it was efficiently competed by
excess unlabeled ETS-A site (lane 3) and stromelysin (St) control site (lane 5) but not by mutant versions of those sites (lanes 4 and 6). Ets-1 protein bound
even more robustly to the mef2c ETS-D element (lane 8). This binding was also specific since it was efficiently competed by unlabeled self competitor (lane 9)
and by the stromelysin (St) control site (lane 11) but not by mutant forms of those sites (lanes 10 and 12).
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site, which was the strongest of the mef2c ETS sites, was
also efficiently competed by excess unlabeled self compet-
itor or by the stromelysin ETS-1 site (Fig. 6B, lanes 9 and
11), but not by mutant versions of those sites (Fig. 6B, lanes
10 and 12).
To test the function of the ETS sites from the mef2c F7
endothelial cell enhancer in vivo, we introduced mutations
into all four of the ETS sites and determined the effect of
those mutations on enhancer function in transgenic embryos
at 9.5 dpc (Fig. 7). In each case, the mutations that we
introduced were the same as those demonstrated to
completely block the ability of those sites to compete for
Ets-1 binding to the stromelysin ETS-1 site in the EMSA
shown in Fig. 6. The wild-type mef2c F7-2 enhancer
construct directed robust expression of h-galactosidase
(Fig. 7A), whereas mutation of all four ETS sites completelyFig. 7. The mef2c endothelial cell enhancer is dependent on Ets factor binding fo
transgenic embryos collected at 9.5 dpc and stained with X-gal. Wild-type (w
throughout the vasculature, including the endocardium (panel A). Mutation of a
transgene activity (panel B). Mutation of the ETS-D element alone in the contex
independent transgenic events analyzed for the mutD transgene, four showed no de
and two showed slightly stronger (st) expression (panel D). Double mutation of
resulted in a complete loss of transgene expression (panel E). V, vasculature. Arrablated enhancer function in seven of seven independent
transgenic events (Fig. 7B).
In the EMSA experiments presented in Fig. 6, the ETS-D
site from mef2c was clearly bound by Ets-1 most robustly
and that site competed for binding to the canonical ETS site
from the stromelysin gene most effectively among the four
mef2c ETS sites. Based on these in vitro observations, we
tested the effect of mutation of the ETS-D site alone on
enhancer function in transgenic embryos. Indeed, mutation
of the ETS-D site had a dramatic effect on enhancer
function. Among eight independent transient transgenic
embryos analyzed at 9.5 dpc, four embryos exhibited no
detectable expression in the endothelium, two embryos
displayed only very weak endothelial expression of lacZ
(Fig. 7C), and two embryos displayed slightly stronger,
although still weak, expression of lacZ (Fig. 7D). Even in
the case of the most strongly expressing lines carrying ar enhancer function in vivo. Lateral views from the right of representative
t) mef2c-F7-2-lacZ transgenic embryos displayed strong lacZ expression
ll four ETS elements in mef2c-F7-2-lacZ (mutABCD) completely ablated
t of mef2c-F7-2-lacZ had a dramatic effect on transgene activity. Of eight
tectable lacZ expression, two showed very weak (wk) expression (panel C)
the ETS-A and ETS-D sites (mutAD) in the context of mef2c-F7-2-lacZ
owheads mark the endocardium.
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level of expression never approached that observed with the
wild-type construct (Fig. 7A). These results indicate that the
ETS-D site is critical for enhancer function in vivo but that
it is not absolutely required since the other three weaker
ETS sites present in the enhancer are able to confer some
activity in the absence of Ets factor binding to the ETS-D
element (Figs. 7C and D).
The results presented in Fig. 6 showed that the ETS-A
site, while not as effective as the ETS-D site at Ets-1
binding, was also a strong ETS element. To test the
possibility that the ETS-A site might confer Ets factor
binding to the mef2c F7 endothelial cell enhancer in the
absence of the ETS-D site, we mutated the ETS-A and ETS-
D sites in combination and examined the effects of the
double mutation on enhancer function in vivo. Mutation of
both sites resulted in a complete disruption of endothelial
cell expression of lacZ in five out of five independent
transgenic founder embryos (Fig. 7E). Taken together, these
results demonstrate that binding of Ets transcription factors
to the ETS sites in the mef2c endothelial cell enhancer is
essential for enhancer function and that mef2c is a direct
transcriptional target of Ets factors in the vascular endothe-
lium through an evolutionarily conserved enhancer.Discussion
Mef2c is an early marker of the vascular endothelium,
and mouse embryos lacking mef2c exhibit profound defects
in vascular organization after initial endothelial cell speci-
fication (Bi et al., 1999; Lin et al., 1998). However, despite
the role of mef2c in vascular development, nothing has been
elucidated previously regarding its transcriptional regulation
in endothelial cells. In this study, we have identified an
intronic enhancer from the murine mef2c gene that directs
robust expression to the developing vascular endothelium
(Fig. 1). We demonstrate that this mef2c endothelial cell
enhancer is active from the earliest stages in vasculogenesis,
with expression detected as early as 7.5 dpc (Fig. 2) and that
this expression is specific to endothelial cells throughout
embryonic development and in the adult (Fig. 3). The mef2c
endothelial enhancer described here contains four highly
conserved, perfect consensus Ets transcription factor bind-
ing sites (Fig. 5) and we show that two of these ETS sites
are completely required for enhancer function in transgenic
embryos (Fig. 7). Thus, these studies place mef2c into a
pathway for vascular endothelial differentiation as a direct
target of members of the Ets family of transcriptional
regulators.
Several members of the Ets transcription factor family
have been shown to be involved in vascular development
and endothelial cell-restricted gene expression (Lelievre
et al., 2001; Oettgen, 2001; Sato, 2001). Ets-1 is expressed
in endothelial cells early in vascular development, and its
expression persists in the vascular endothelium throughoutembryogenesis (Maroulakou et al., 1994). Ets-1 has been
implicated in the transcriptional regulation of several genes
essential to endothelial cell development, such as Flt-1 and
Flk-1 (Kappel et al., 2000; Wakiya et al., 1996), and Ets-1
has been shown to be a key transcriptional mediator of
angiogenesis in endothelial cells (Oda et al., 1999). Here,
we have shown that Ets-1 binds efficiently to the ETS sites
in the mef2c endothelial-specific enhancer (Fig. 6), and that
mutations that disrupt this binding result in complete
ablation of transcriptional activation in vivo (Fig. 7). We
consider it likely that additional Ets factors are also direct
activators of mef2c via the vascular endothelial enhancer
described here. This hypothesis is based on the observation
that the Ets domain, which mediates DNA binding, is highly
conserved within this family of factors. As such, all Ets
proteins recognize the same core DNA sequence, and many
Ets factors show similar binding preference for the extended
recognition sequence, including the nucleotides flanking the
core (Graves and Petersen, 1998; Sharrocks et al., 1997).
The Ets factors Fli-1, Erg, and TEL are all known to be
expressed early during embryogenesis (Spyropoulos et al.,
2000; Vlaeminck-Guillem et al., 2000; Wang et al., 1997),
and targeted disruption of either TEL or Fli-1 in mice results
in embryonic lethality due to vascular defects (Hart et al.,
2000; Spyropoulos et al., 2000; Wang et al., 1997). NERF-
2, another member of the Ets family, has been shown to be a
key regulator of the Tie and Tie-2 promoters (Dube et al.,
1999; Iljin et al., 1999), and its expression in endothelial
cells suggests it may also serve to regulate mef2c tran-
scription in vivo (Iljin et al., 1999).
The Ets factors important in vascular endothelial cell
transcriptional regulation are also expressed in other regions
of the developing embryo (Maroulakou et al., 1994; Oettgen
et al., 1996; Spyropoulos et al., 2000; Vlaeminck-Guillem
et al., 2000; Wang et al., 1997). As such, Ets factors in the
vasculature and in other lineages function in combination
with other transcription factors to mediate lineage-specific
transcription (Sharrocks, 2001; Verger and Duterque-
Coquillaud, 2002). In the vascular endothelium, activation
of the Flt-1 promoter has been shown to require an ETS
binding site and a cAMP response element (Wakiya et al.,
1996). Similarly, the regulation of Flk-1 involves binding
sites for the bHLH protein SCL/Tal-1 and a GATA element,
in addition to two ETS binding sites (Kappel et al., 2000).
Like the expression of these two VEGF receptor genes, the
expression directed by the mef2c enhancer described here is
also restricted to the vascular endothelium. Therefore, it is
likely that members of other transcription factor families
cooperate with Ets factors in the regulation of the
endothelial-specific mef2c enhancer described here. Alter-
natively, the mef2c enhancer described here may be targeted
by multiple Ets proteins that each function through different
ETS sites present in the enhancer (Fig. 5). This could result
in activation of the enhancer only in the endothelium due to
the appropriate expression of multiple different Ets proteins,
as has been shown for some Ets-dependent genes in other
S. De Val et al. / Developmental Biology 275 (2004) 424–434 433lineages (Li et al., 2002; O’Reilly et al., 2003). Future
studies will focus on whether the Ets-dependent regulation
of the mef2c endothelial enhancer is dependent on
cooperative interactions of Ets with other classes of factors
or among different members of the Ets family itself.
Targeted disruption of the mef2c gene in mice has
demonstrated the importance of MEF2 function in the
development of the vascular system (Bi et al., 1999; Lin
et al., 1998), although the precise role of mef2c in the
endothelium remains to be determined. Mef2c null mice die
by 9.5 dpc with profound cardiac and vascular defects (Bi et
al., 1999; Lin et al., 1997, 1998). In the yolk sacs of mef2c
null mice, a primary vascular network is formed but fails to
undergo proper remodeling, resulting in large, poorly
defined immature vessels (Bi et al., 1999; Lin et al.,
1998). The vascular defects seen in the embryo ranged from
complete absence of major vessels to the presence of
abnormally formed vessels. Abnormal variability in vessel
diameter and loss of vascular complexity was detected, as
was less vascular branching (Bi et al., 1999; Lin et al.,
1998). While endothelial cells are present in the absence of
MEF2C, they fail to organize properly, suggesting a
potential role for MEF2C in endothelial cell differentiation
(Bi et al., 1999; Lin et al., 1998). Unfortunately, the
endothelial phenotype in mef2c null mice may be partially
obscured by the importance of MEF2C in other cell types,
particularly the heart. In addition to the vascular defects,
mef2c null mice exhibit a severe cardiac phenotype,
including a nearly complete loss of right ventricle and
outflow tract, defective looping, and a disorganized endo-
cardium (Lin et al., 1997). These defects result in reduced
cardiac function and could contribute to the observed
vascular defects. Our results demonstrate that the mef2c
gene contains an endothelial-specific enhancer that is active
from the earliest stages in vascular development, suggesting
a primary role for MEF2C in endothelial cell differentiation.
However, to clearly define the role of this factor in
endothelial cell differentiation, it will be necessary to
conditionally inactivate mef2c only in endothelial cells.
The role of mef2c in the vasculature is not restricted to
expression within the endothelial cells. Mef2c transcripts are
also detected in the smoothmuscle cells of vessels throughout
embryonic development (Edmondson et al., 1994; Lin et al.,
1998). Mice lacking MEF2C did not have differentiated
smooth muscle cells in the vasculature, although it is not clear
whether this reflects a primary requirement for MEF2C in
smooth muscle cell differentiation or a secondary conse-
quence of cardiac or endothelial defects (Lin et al., 1998). The
mef2c enhancer described in this paper drives expression
specifically in endothelial cells, with no expression ever
detected in vascular smooth muscle (Fig. 3), supporting the
notion that additional, discrete elements within the mef2c
locus will direct expression to smooth muscle. Indeed, we
have recently identified a distinct enhancer that appears to
direct expression to the majority of smooth muscle in the
developing mouse embryo, including vascular smoothmuscle but not the vascular endothelium (SDV and BB,
unpublished observations).
The identification of a discrete enhancer from the mef2c
gene that is sufficient to direct expression solely to the
vascular endothelium further supports a model for mef2c
gene regulation based on the independent regulation of
multiple modular enhancers. We have previously described
two other enhancers from mef2c that direct expression
exclusively to skeletal muscle (Dodou et al., 2003) and to
the anterior regions of the secondary heart field (Dodou et al.,
2004). We have also identified additional separate, modular
enhancers frommef2c that independently direct expression to
smooth muscle (SDVand BB, unpublished observations) and
to neural crest (JA and BB, unpublished observations). The
evolution of multiple independent transcriptional enhancers
provides a potential mechanism for regulatory diversity by
allowing gene expression to be controlled in a very fine-tuned
manner in each lineage wheremef2c is expressed. Our results
clearly demonstrate that each of the mef2c enhancers
identified to date function independently outside of the
context of the mef2c locus. It will be interesting to determine
whether these enhancers are truly independent modules or
whether their regulation is interdependent in the context of
the entire mef2c locus and if these enhancers are required for
mammalian development in vivo.Acknowledgments
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